Abstracts tagged "interleukins (IL) and vasculitis"

Abstract Number: 871 • 2016 ACR/ARHP Annual Meeting
Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis
Anne-Claire Desbois¹, Aurélie LEROYER², Marlène Garrido³, Julien Gaudric⁴, Cloé Comarmond⁵, David Klatzman⁶, Philippe Cluzel⁷, Pierre Fouret⁸, Laurent Chiche⁹, Fabien Koskas¹⁰, Gilles Kaplanski¹¹, Patrice Cacoub¹² and David Saadoun¹³, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Faculté de Pharmacie, Marseille, France, ³I3 laboratory, Pitié-Salpétrière, Paris, France, ⁴Department of Vascular surgery GHPS, Paris, France, ⁵DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁶UPMC Université Paris 06, UMR 7211, Paris, France, ⁷Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, ⁸Hôpital La Pitié Salpétrière, Paris, France, ⁹Service de Chirurgie Vasculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹⁰Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ¹¹Aix-Marseille Université - Internal Medicine hopital conception - F-13000 Marseilles, Marseille, France, ¹²Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: Large vessels vasculitis (LVV) include Takayasu disease (TD) and Giant Cell Arteritis (GCA). Interleukin 33 (IL-33) is a cytokine which controls immune responses and…
Abstract Number: 884 • 2014 ACR/ARHP Annual Meeting
Interleukin 6 Does Not Upregulate Pro Inflammatory Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis
Lorraine O'Neill¹, Jennifer McCormick², Wei Gao², Conor Murphy³, Geraldine M. McCarthy⁴, Douglas J. Veale⁵, Ursula Fearon² and Eamonn S. Molloy¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁴Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁵Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Interleukin 6 (IL 6) is postulated to play a role in the pathogenesis of Giant Cell Arteritis. Several studies have demonstrated increased circulating IL…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].